RPL35A

Across TCGA pan-cancer cohorts, RPL35A RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of RPL35A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPL35A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL35A is over-expressed in tumor, although a few such as BRCA and KICH show the opposite, repressed pattern.

KIRC, LIHC, and COAD are the cancer types where RPL35A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL35A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	III,IV	+1.040	<.001	12	view →
LIHC	Female	II,III,IV	+1.219	<.001	9	view →
COAD	Female	II,III,IV	+0.864	<.001	9	view →
HNSC	Male	IV	+1.024	<.001	8	view →
KIRP	All	II,III,IV	+0.633	.001	8	view →
LUSC	All	All	+0.949	<.001	6	view →
CHOL	Male	All	+2.471	<.001	5	view →
BRCA	Female	All	−0.309	<.001	4	view →
KICH	Female	All	−0.949	.001	3	view →
PRAD	All	All	+0.250	.013	2	view →
READ	All	All	+0.519	.039	1	view →
ESCA	All	All	+0.497	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

RPL35A–KIRC

Open the KIRC breakdown →